...a serotonin 5-HT2C receptor agonist; Orexigen Therapeutics Inc. ’s Contrave naltrexone/bupropion, a MOR antagonist; and Vivus Inc.... ...La Jolla, Calif. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland University of New South Wales, Sydney, Australia Vivus Inc....
...enlarge the GLP-1 market.” Lars Fruergaard Jørgensen, Novo Nordisk The next largest obesity product was Vivus Inc.... ...the three obesity drugs launched over 2012-14, with placebo-adjusted reductions in body weight of 3.5-9.4%. Vivus... ...A/S (CSE:NOVOB; NYSE:NVO), Bagsvaerd, Denmark Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland University of Oxford, Oxford, U.K. Vivus Inc....
...Selten granted Vivus exclusive, worldwide rights to develop and commercialize tacrolimus and ascomycin to treat pulmonary... ...financial terms, and Selten referred questions to Vivus. Selten Pharma Inc. , San Carlos, Calif. Vivus Inc.... ...Selten Pharma Inc. , San Carlos, Calif. Vivus Inc. (NASDAQ:VVUS), Campbell, Calif. Business: Cardiovascular
Nora Weintraub
Selten Pharma Inc.
Vivus Inc....
...to commercialize erectile dysfunction drug Stendra avanafil in the U.S., Canada, South America and India. Vivus... ...will be responsible for undisclosed royalties payable to Mitsubishi Tanabe Pharma Corp. (Tokyo:4508, Osaka, Japan). Vivus... ...Japan, China and certain other Pacific Rim countries. Stendra is a fast-acting phosphodiesterase-5 (PDE-5) inhibitor. Vivus Inc....
...a serotonin 5-HT2C receptor agonist; Orexigen Therapeutics Inc. ’s Contrave naltrexone/bupropion, a MOR antagonist; and Vivus Inc.... ...La Jolla, Calif. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland University of New South Wales, Sydney, Australia Vivus Inc....
...enlarge the GLP-1 market.” Lars Fruergaard Jørgensen, Novo Nordisk The next largest obesity product was Vivus Inc.... ...the three obesity drugs launched over 2012-14, with placebo-adjusted reductions in body weight of 3.5-9.4%. Vivus... ...A/S (CSE:NOVOB; NYSE:NVO), Bagsvaerd, Denmark Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland University of Oxford, Oxford, U.K. Vivus Inc....
...Selten granted Vivus exclusive, worldwide rights to develop and commercialize tacrolimus and ascomycin to treat pulmonary... ...financial terms, and Selten referred questions to Vivus. Selten Pharma Inc. , San Carlos, Calif. Vivus Inc.... ...Selten Pharma Inc. , San Carlos, Calif. Vivus Inc. (NASDAQ:VVUS), Campbell, Calif. Business: Cardiovascular
Nora Weintraub
Selten Pharma Inc.
Vivus Inc....
...to commercialize erectile dysfunction drug Stendra avanafil in the U.S., Canada, South America and India. Vivus... ...will be responsible for undisclosed royalties payable to Mitsubishi Tanabe Pharma Corp. (Tokyo:4508, Osaka, Japan). Vivus... ...Japan, China and certain other Pacific Rim countries. Stendra is a fast-acting phosphodiesterase-5 (PDE-5) inhibitor. Vivus Inc....